Blindness News and Research

RSS

High-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked development of glaucoma

In a discovery that could point to new treatments for a wide range of neurodegenerative diseases, Jackson Laboratory researchers have found that high-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked the development of glaucoma, by preventing neurodegeneration.

14 Mar 2005

Gene identified that confers susceptibility to age-related macular degeneration

By combining the tools of high-throughput biology and statistical genetics, scientists at Rockefeller University, Yale University School of Public Health and the National Eye Institute have identified a gene that confers susceptibility to age-related macular degeneration (AMD), the most common cause of vision loss in the United Sates for those over 60.

14 Mar 2005

Gene for AMD has now been identified by researchers

Age-related macular degeneration (AMD) is a debilitating eye disease affecting about 15 million people in the United States.

13 Mar 2005

Biomedical engineers, chemists collaborate on novel method to design better medicines

The ability to select and develop compounds that act on specific cellular targets has just gained a computational ally -- a mathematical algorithm that predicts the precise effects a given compound will have on a cell's molecular components or chemical processes.

8 Mar 2005

FDA has accepts new drug application for Exubera (inhaled human insulin powder)

Dr. John Patton, co-founder and chief scientific officer for Nektar reported that Pfizer and The Sanofi-Aventis Group have announced that the FDA has accepted for filing a new drug application for Exubera (inhaled human insulin powder).

3 Mar 2005

Mutations in newly discovered gene, NPHP5 cause Senior-Loken syndrome

Scientists at the University of Michigan Medical School have discovered a gene called NPHP5 and found mutations in this gene that cause a rare genetic disease called Senior-Loken syndrome. Children with this syndrome develop a type of cystic kidney disease called nephronophthisis, as well as a form of blindness called retinitis pigmentosa.

3 Mar 2005

Encouraging results in wet age-related macular degeneration study

Novadaq Technologies has announced that Dr. Giovanni Staurenghi, (Associate Professor of Ophthalmology, Department of Otorhinolaryngological and Ophthalmological Science University of Milan, Italy), reported preliminary data on 24-patients in an on-going study using the Company's proprietary technology to treat wet Age-Related Macular Degeneration (AMD).

28 Feb 2005

First study to show cost-effectiveness of pre-diabetes intervention

More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.

28 Feb 2005

Childhood obesity is a serious health problem in Australia

Professor Michael Booth, co-director of the University of Sydney's Centre for Overweight and Obesity, said teenagers were already showing signs of serious illness caused by their weight.

24 Feb 2005

Scientists have regenerated a damaged optic nerve

This achievement, which occurred in laboratory mice and is described in the March 1, 2005 issue of the Journal of Cell Science, holds great promise for victims of diseases that destroy the optic nerve, and for sufferers of central nervous system injuries.

24 Feb 2005

Researchers have identified a protein called HIF-2a, which is important in retina formation

Hoping to prevent blindness in premature babies, UT Southwestern Medical Center researchers have identified a protein that responds to oxygen levels in cells and tissues and also affects the developing eye.

22 Feb 2005

Oak Ridge technology used to understand semiconductor defects helps people at risk of becoming blind

Millions of people at risk of becoming blind could one day be helped by an Oak Ridge National Laboratory technology originally intended to understand semiconductor defects.

10 Feb 2005

Euro funding for diabetes and exercise research

Researchers at The University of Nottingham are among a network of European scientists who have been awarded €12.7 million (around £8.7 million) for a study into the relationship between lack of exercise and the development of diabetes — and the health benefits of regular exercise in its prevention and cure.

12 Jan 2005

Vital research into the effects of premature birth throughout childhood

Results of a follow-up study into babies born extremely prematurely was published last week (Thursday 6 January) in the New England Journal of Medicine.

10 Jan 2005

High rate of disability in extremely premature babies, new research results reveal

The follow-up results of a major study into babies born extremely prematurely have revealed that a high number of these children have a disability, although the levels of severity vary widely.

10 Jan 2005

New guidelines for treating diabetes

Every year, the American Diabetes Association (ADA) issues Clinical Practice Recommendations, a series of updated recommendations to help health care providers treat people with diabetes using the most current research available.

7 Jan 2005

Herpes virus is everywhere and it's unavoidable

While not the first, the researchers report that this study uses the most sensitive techniques in a cross-sectional assessment performed to date of the presence of HSV-1 DNA in the eyes and mouths of healthy individuals, in terms of population size and total samples collected.

6 Jan 2005

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD), according to a paper in the Dec. 30 issue of the New England Journal of Medicine. Macugen was approved by the Food and Drug Administration on Dec. 17.

30 Dec 2004

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

20 Dec 2004

Accumulated exposure to lead may be an important but unrecognized risk for developing cataracts in men

Lead continues to pose a significant public health problem in spite of substantial reductions in lead exposure in the United States in the recent past, according to background information in the article.

8 Dec 2004